Ultimovacs held its presentation of the company’s H1-19 report on 21 August 2019 (08:00) at Oslo Cancer Cluster Innovation Park (Ullernchausséen 64) in Jónas Einarsson Auditorium.
The presentation was recorded and can be found here
H1-19 report and presentation
News
On 5 August 2019, FIL Limited disclosed additional purchase of shares in Ultimovacs bringing the total holding above 5%.
Technology
Ultimovacs is developing a universal cancer vaccine applicable across a broad spectrum of cancer types.
Clinical studies
Lead product tested in three clinical trials, strong results justifies the initiation of a registration trial.